New drug LIVTENCITY tracked in Real-World use for transplant patients with CMV
NCT ID NCT06555432
First seen Nov 18, 2025 · Last updated May 04, 2026 · Updated 23 times
Summary
This study monitors how safe and effective the drug LIVTENCITY (maribavir) is for adults who develop CMV infection after an organ transplant. About 168 participants in South Korea will be followed for 20 weeks during routine care. The goal is to see how well the drug works in everyday medical practice and to track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Seoul ST. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.